CTLA4 and ovarian carcinoma: Particularly, single-agent Abs against CTLA-4, PD-1 or PD-L1 revealed modest results in epithelial ovarian cancer with median response rates (RR) less than 15% and a control of disease rate less than 50% [25,26].